Ultragenyx Pharmaceutical Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$673M
Cost of Revenue
—
R&D
$750M
SG&A
$349M
D&A
$35M
Operating Income
$-535M
EBITDA
$-500M
Interest Income
$25M
Other Income/Expense
$-61M
Pretax Income
$-571M
Tax Provision
$4M
Net Income
$-575M
Operating Margin
-79.5%
Net Margin
-85.4%
Effective Tax Rate
-0.7%
Deferred Tax Assets
$6M
Deferred Tax Liabilities
$30M
DTA Valuation Allowance
$1.35B
Tax Credit Carryforwards
$426M
NOL Carryforwards
$511M
ETR (Continuing Operations)
-0.7%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
—
ETR Foreign Differential (pp)
-0.4%
Operating Lease Cost
$12M
Revenue YoY Variation
20.2%
Income YoY Variation
0.2%